ST
stuart_roberts
Community Contributor
Member since 2025
Views408Total number of views
Followers5Total number of followers
Comments0Total number of comments
Life sciences equity analyst with a passion for biotech and healthcare investing. Founder of NDF Research and co-founder of Pitt Street Research, known for turning complex science and technology into clear, investable ideas
https://pittstreetresearch.com/
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
408
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
ST
US$21.53
71.2% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67